

selected from a polypeptide, an antibody, and an antigen; and (II) a fluid selected from a gas and a liquid.

The Applicants hereby elect, without traverse, Group II (*i.e.*, claims 13–21). The Applicants hereby withdraw claims 1–12, but expressly reserve the right to file one or more divisional application(s) directed to the subject matter of the non-elected claims present in the application (*i.e.*, claims 1–12).


In addition, the Applicants note that the Examiner has required a restriction between product and process claims. Accordingly, as the process claims (*i.e.*, claims 1–12) currently include all the limitations of independent product claim 13, the Applicants respectfully request that claims 1–12 be rejoined, in accordance with the provisions of M.P.E.P. § 821.04(b), if independent product claim 13 is found to be allowable.

Claims 1–21 will be pending upon entry of this paper.

CONCLUSION

Applicants respectfully request that the application now proceed promptly to examination. If the Examiner believes that a telephone conversation with the Applicants' attorney would expedite the allowance of this application, the Examiner is invited to call the undersigned attorney at (617) 570-1973.

Respectfully submitted,



Kenneth E. Radcliffe, Esq.
Attorney for the Applicants
Goodwin | Procter LLP
Exchange Place
Boston, Massachusetts 02109

Date: August 28, 2006
Limited Recognition No. L0081

Tel. No.: (617) 570-1973
Fax No.: (617) 523-1231
Customer No. 051414

LIBA/1725121.1